VXRC, PPTO, SLAT, BBYB, QMCI
DCGN, NPWS, RNN, ICOG, BVTI, SIRI
Our Stocks to Watch today include Vortex Resources Corp. (OTCBB: VXRC), Precision Petroleum Corp. (OTCBB: PPTO), Superlattice Power Inc. (OTCBB: SLAT), Baby Bee Bright Corp. (OTC: BBYB), QuoteMedia, Inc. (OTCBB: QMCI), deCODE Genetics (Nasdaq: DCGN), NEAH Power Systems Inc. (OTCBB: NPWS), Rexahn Pharmaceuticals Inc. (Amex: RNN), ICO Global Communications (Holdings) Ltd. (Nasdaq: ICOG), Biovest International Inc. (OTC: BVTI) and SIRIUS XM Radio Inc. (Nasdaq: SIRI).
VORTEX RESOURCES CORPORATION (OTCBB: VXRC)
"Up 13.29% in morning trading"
The Company's business has been the identification and acquisition of undervalued assets within emerging industries for the purpose of consolidation and development of these businesses and sale if favorable market conditions exist. The Company's objective is to find, acquire and develop resources at the lowest cost possible and recycle its cash flows into new projects yielding the highest returns with controlled risk. The Company's competencies include financial services, mergers and acquisitions, accounting, real estate development, and natural resources exploration. The Company is currently in the process of developing a logistics center. As part of its strategy to develop a logistics center, the Company has entered a term sheet with Yasheng Group in which Yasheng Group, among other things, has agreed to contribute real property for the development of a logistics center. Further, the Company and Yasheng Group have jointly entered into a cooperation agreement with Legend Transportation based in Texas. As a result of the above, the Company is in the process of changing its name to Yasheng Eco-Trade Corporation.
Vortex Resources Signs Agreement to Establish Yasheng Group Russia
Enters MOU with Create Agrogroup for Stock Breeding Complex in Russia
Vortex Resources Corp. (OTCBB: VXRC) (Equity, ISIN US92905M2035, WKN A0RLEK, HTE2), which is in the process of changing its name to Yasheng Eco-Trade Corporation, has signed an Agreement creating the Yasheng Group Russia. The Yasheng Group Russia, as part of a Joint Venture with Create Agrogroup Zao (“Create”), will be developing an Eco-Trade distribution and logistics center in Russia similar to the one the company is currently working on in Southern California.
The joint venture is the culmination of several months of negotiations headed by former Prime Minister of Tajikistan and ambassador to Russia Abdoumalik Abdoulladjanov. The first stage of the development is a Stock Breeding Complex in the Russian Federation. The purpose of the development will be to increase exports to China, which management believes will be a significant opportunity for the company. Create has been working for several years acquiring over 220 acres of land and has recently received approval to begin stage one of the developments.
The development is expected to be built out in three stages over five years at an estimated cost of $186 million.
The development of the joint venture in Russia is contingent upon the completion of due diligence by all parties, executing definitive agreements and raising the needed capital. As such, there is no guarantee that we will be successful in development of this joint venture.
ABOUT CREATE AGROGROUP
Create Agrogroup ZAO was established in January 2006 in Balakovo of Saratov region for the operational management of “Saratov Agricultural Group” Project implementation. Managers of company have extensive experience of agricultural project implementation.
PRECISION PETROLEUM CORPORATION (OTCBB: PPTO)
Precision Petroleum Corporation is an independent energy company engaged in the acquisition, exploration and development of oil and natural gas properties in the United States. Precision's objective is to seek out and develop opportunities in the oil and natural gas sectors that represent a low risk opportunity. As well, Precision aims to define larger projects that can be developed with Joint Venture partners.
June 25 -
Precision Petroleum Corporation-Acquires Working Interest in the Ward/McNeil #1 Well, Garvin County, Oklahoma
Precision Petroleum Corp. (OTCBB: PPTO) (the "Company") has recently completed the purchase of a working interest in an oil and gas lease in Garvin County, Oklahoma.
Ward/McNeil #1 represents the 13th working interest purchased by the Company over the past 2 months.
This well was initially completed in the Basal Pennsylvanian Sandstone/Viola Limestone reservoirs after a minor frac entry into these formations.
The well was producing approximately 12 barrels of oil and 100 MCF of natural gas per day after the initial treatment. The Company intends to re-enter these formations with a major frac which should substantially increase the production capacity of the reservoirs.
Richard Porterfield, Petroleum Geologist and President, is pleased with this acquisition. Although the well is presently considered a minor producer, we anticipate that we will be able to quickly recover our investment and extended profits after the re-completion is finalized.
Mr. Porterfield also stated that he and other oil and gas consultants are presently assessing the acquisition of a 6 well producing package. This operation also has an abundance of spacing for a further 6 well expansion development, with multiple reservoirs. In view of current commodity prices, this addition would be a major boost to the Company's cash flow and bottom line profits. Negotiations have commenced during which various technical analysis examinations and reservoir evaluation programs by the Company are underway.
POWER INCORPORATED (OTCBB: SLAT)
"Up 12.70% in morning
Inc. was incorporated in Nevada in
2004 and is a development stage technology company
that is focusing its resources and efforts on the
development and marketing of lithium-powered vehicles
and products, as well as on commercial and residential
properties. Everything from scooters, bicycles, mopeds,
motorcycles, cars and homes are being converted successfully
to zero-emission, lithium-powered vehicles and facilities.
June 24 -
Superlattice Power Inc. Research Group Successfully Increased the Efficiency of Lithium Ion Battery
Superlattice Power Inc. (OTCBB: SLAT), an emerging leader in the development and marketing of the next generation of lithium-powered batteries worldwide, states that by using 29.6 kilo watt hours of lithium ion battery the researchers of SLAT investigated the factors that affect lithium ion diffusion and origin of high resistance in a large format battery pack.
In initial research, the charging algorithm was modified using a multistage charging rate following a differential curve obtained through experiment. The development work also emphasized on electrical regenerative power and cell voltage balancing using a new version of battery management system.
The new technology was used by EV Innovations Inc. and the driving range of the electric car has been increased by at least 1.5 times. Further research work will be continued with a next generation battery pack where the cathode material with superlattice structure will be used and the expected specific capacity is 1.5 times compared to the cathode, LiMnxNiyCozO2.
The objective of Superlattice Power Inc. is to manufacture and develop a safe rechargeable lithium ion battery for onboard energy storage in HEVs and EVs. The technical success of the company is ensured by its proprietary battery module design, battery cell management systems and battery thermal management system. Superlattice Power has a team well trained in lithium ion battery technology and its large-scale manufacturing is receiving support from different manufacturers worldwide.
BEE BRIGHT CORPORATION (OTC: BBYB)
Baby Bee Bright Corporation
manages the Baby Bee BrightTM brand. Its executive
staff, composed of professionals with over 30 years
of experience in engineering research and marketing,
have developed an innovative prenatal communication
system, servicing the rapidly expanding expectant
mother/prenatal market. The company has a patented,
audio directional technology for its communicator
which is designed for expectant mothers to safely
and efficiently transmit music and sound to their
babies. It allows mothers and family to bond with
their babies before birth. Lullabies and classical
music provide the baby with soothing sounds before
and after birth.
Baby Bee Bright Corporation To Create New Product
Baby Bee Bright Corporation (OTC:
BBYB), developer of a unique prenatal communication
system is in the planning stage to develop a professionally
shot video to help inform the public about the features
and benefits of the Baby Bee Bright System and to
also help educate expectant mothers on how to most
effectively use the system. The company’s video
will show the public and the expecting mothers the
proper ways to use the communicator and the correct
positioning of the speakers so that a mother’s
unborn child can receive the best benefits from the
Fred Dahlman, CEO, states: “We
think a professionally developed video will help to
visually demonstrate the simplicity and effectiveness
of using the Baby Bee Bright prenatal communication
system. This new video can also help to explain the
system’s features and benefits to potential
users and should spur consumer interest in the product,
interest and inquiries from prospective retailers,
and ultimately new sales and product revenue. We intend
to post our video on the company’s web site
and we will also post it on YouTube.com which has
enormous traffic and should help create interest and
drive new sales. We think this video will ultimately
be a boon for the company’s bottom line and
we look forward to a positive public response to the
video and ultimately increased sales.”
QUOTEMEDIA INCORPORATED (OTCBB: QMCI)
Inc. is a leading software developer
and provider of real-time streaming financial market
information, decision-support, news and research solutions
to brokerage, financial services companies, business
and media corporations. Among its many leading-edge
products lines, the Company offers data feeds, news,
dynamic market content solutions, interactive stock
research tools, financial applications and real-time
wireless applications. QuoteMedia provides data and
services for companies such as the NASDAQ, the OTCBB,
Dow Jones & Company, Forbes.com, Scotia Capital,
Business Wire, Southwest Securities, Regal Securities,
FBR Direct, Broadridge Financial Solutions, Inc.,
AIM Trimark, Zacks Investment Research, ChoiceTrade,
QTrade, Schaeffer's Investment Research, Automated
Financial Systems, WallStreet*E, and others. For more
information, visit www.quotemedia.com.
June 3 - QuoteMedia Announces Enterprise Agreement with TradePMR
QuoteMedia, Inc. (OTCBB: QMCI), a leading provider of market data, corporate research information and financial applications, announced an enterprise agreement with TradePMR, Inc. TradePMR is a major provider of brokerage and custody services, and related technology, to the financial services industry.
TradePMR will integrate a wide array of QuoteMedia’s offerings into its eCustody platform, which it currently provides to 420 independent RIA firms for use by their investment advisors.
Contracted QuoteMedia services include raw quote and research data via QuoteMedia’s DataFeed solutions, and an extensive array of QuoteMedia’s content and research products. In addition, TradePMR will provide its clients with QuotestreamTM Professional and Quotestream Wireless, QuoteMedia’s streaming real-time portfolio management system for brokers and financial advisors.
"In order to maintain and improve our competitive position, it is vital that we continue to provide our clients with unmatched market and research information, timely data, technological excellence and the highest level of customer service. By incorporating QuoteMedia's market solutions into our new and existing offerings, we are able to go the extra step in creating an outstanding offering for our clients," says Robb W. Baldwin, President and CEO of TradePMR. "With QuoteMedia's superior technologies and breadth of market coverage, we are able to expand the depth of our financial data content to provide the timely, in-depth market information our clients require."
"We're very pleased to be partnering with TradePMR," says Dave Shworan, CEO of QuoteMedia Ltd. "TradePMR has a well deserved reputation for providing brokerage firms and financial advisers with the information, technology and support they need to manage clients' investments effectively and grow their business efficiently. Certainly this agreement represents a major growth opportunity for QuoteMedia, particularly with respect to increasing market acceptance for Quotestream Professional. To have a company like TradePMR choose to incorporate our solutions in such a wide-ranging manner represents a major endorsement of the quality of our offerings, and this is especially gratifying."
TradePMR is a privately held brokerage firm (Member FINRA/SIPC) located in Gainesville, Florida. Since 1999, it has been a leading provider of Brokerage and Custody services to Independent Registered Investment Advisors (RIAs) and their clients by providing an integrated web-based workstation that enables RIAs to run their practices more efficiently and effectively.
DECODE GENETICS INCORPORATED (NASDAQ: DCGN)
"Up 44.42% in morning trading"
deCODE is a biopharmaceutical company applying its discoveries in human genetics to the development of diagnostics and drugs for common diseases. deCODE is a global leader in gene discovery — our population approach and resources have enabled us to isolate key genes contributing to major public health challenges from cardiovascular disease to cancer, genes that are providing us with drug targets rooted in the basic biology of disease. Through its CLIA-registered laboratory, deCODE is offering a growing range of DNA-based tests for gauging risk and empowering prevention of common diseases, including deCODE T2™ for type 2 diabetes; deCODE AF™ for atrial fibrillation and stroke; deCODE MI™ for heart attack; deCODE ProCa™ for prostate cancer; deCODE Glaucoma™ for a major type of glaucoma. deCODE is delivering on the promise of the new genetics.
June 29 -
deCODE Discovers a Gene Linked to Risk of Kidney Stones and Osteoporosis
Findings Offer Promising Target for Drugs to Better Regulate Calcium Metabolism, Are Integrated Into deCODEme™
A discovery by scientists at deCODE Genetics (Nasdaq: DCGN) and academic colleagues from Iceland, the Netherlands and Denmark has pointed to a common biological mechanism contributing to both kidney stones and decreased bone mineral density (BMD). About 60% of the population carry two copies of a single-letter variation in the human genome (SNP) on chromosome 21, putting them at roughly 65% greater likelihood of developing kidney stones than those who carry no copies. This single variant may thus account for more than a quarter of the incidence of kidney stones, and in women carriers it is also associated with decreased BMD at the hip and spine. The study, which involved the analysis of the genomes of some 50,000 patients and controls, is published in the online edition of Nature Genetics at http://www.nature.com/ng and will appear in upcoming print edition of the journal.
The SNP is in the gene encoding claudin 14 (CLDN14), a protein expressed in the kidney and one of a family of membrane proteins that regulate the passage of ions and small solutes between cells. As calcium is a key component both of most kidney stones and of bone, the deCODE team examined the relationship between CLDN14 and the metabolism of calcium. The results suggest that the SNP may be contributing to increased calcium excretion in urine, a major risk factor for kidney stones and also a sign of bone loss.
"This is an exciting finding because it uncovers a highly plausible common biological mechanism leading to two diseases. This offers a potentially attractive new pathway for drug discovery, and the next task is to build on our understanding of how this SNP increases risk of these diseases and how this pathway could be targeted therapeutically to address this risk. As ever, deCODEme subscribers will see this new variant in their profiles, and we look forward building on this discovery," said Kari Stefansson, CEO of deCODE.
ABOUT KIDNEY STONES
Kidney stones are small crystals formed of dissolved minerals, mainly calcium, that form in the kidneys. Smaller stones can simply be passed through urination, though larger ones can block the urinary tract, causing considerable pain and bleeding. Kidney stones affect some 5% of women and 10% of men in the industrialized world. Larger stones can be detected with ultrasound screening and broken up to facilitate passage, though the recurrence rate is high.
deCODE would like to thank all those who participated in this study, as well as the collaborating clinicians and scientists from the Landspitali University Hospital in Reykjavik, Iceland; Radboud University Nijmegen Medical Centre in Nijmegen, Netherlands; Nordic Bioscience A/S in Herlev, Denmark; and the Center for Clinical and Basic Research A/S in Ballerup, Denmark.
NEAH POWER SYSTEMS (OTCBB: NPWS)
"Up 63.02% in morning trading"
NEAH Power Systems, Inc. (NPWS) is developing long-lasting, efficient and safe power solutions for the military and for portable electronic devices. NEAH uses a unique, patented, silicon-based design for its micro fuel cells that enable higher power densities, lower cost and compact form-factors. The company's micro fuel cell system can run in aerobic and anaerobic modes.
June 25 -
NEAH Successfully Tests Anaerobic Direct Methanol Fuel Cell Prototype
NEAH Power Systems, Inc. (OTCBB: NPWS), the Company developing fuel cells for the military and portable electronic devices, announced today it has successfully demonstrated a new type of low cost, high reliability and power, liquid electrolyte based direct methanol fuel cell that does not require air to operate. This is the first major innovation in fuel cell technology in over 20 years, where a repeatable, reliable non-PEM based system has been successfully introduced and demonstrated in sustained operation.
The prototype was self contained and sized to generate 8W of gross power, fuel cartridges were replaced multiple times and repeatable performance demonstrated. A video of the technology, markets that NEAH serves, and demonstration of the technology will be posted on YouTube, as well as on the company's website, www.neahpower.com, and NEAH has invited any interested parties to visit the company to see the system in operation.
"We are thankful to the Office of Naval Research for funding significant portions of this research. This technology is singular in that it can operate in places where air isn't available," Dr. Chris D'Couto, NEAH's President and Chief Executive Officer, noted. "This system can service many specialized markets, such as underwater and surface water manned and unmanned vehicles, as well as numerous aerospace applications, and will be the building block for fuel cell solutions for Hobie Cat and other key customers." NEAH fuel cells operate in both an aerobic and anaerobic manner. "Our micro fuel cells may eventually replace batteries for most uses," D'Couto said, "meaning that cost-efficient and 'green' technology is at hand to not only preserve the environment, but to provide nearly perpetual power to the military, manufacturers of almost any product that require an energy source, and to the millions of consumers who require energy on the go."
REXAHN PHARMACEUTICALS INCORPORATED (AMEX: RNN)
in morning trading"
Rexahn Pharmaceuticals is a clinical stage pharmaceutical company dedicated to commercializing first in class and market leading therapeutics for cancer, CNS disorders, sexual dysfunction and other unmet medical needs. Rexahn currently has three drug candidates in Phase II clinical trials — Archexin, Serdaxin, and Zoraxel — all potential best in class therapeutics, and a robust pipeline of preclinical compounds to treat multiple cancers and CNS disorders. Rexahn also has key R&D programs in cancer nano-medicines and multi-target aimed ligands drug discovery technologies.
June 29 -
Rexahn Pharmaceuticals Signs Development and Commercialization Agreement with a Top 20 Pharmaceutical Company for Novel Anti-cancer Compound
Rexahn Pharmaceuticals, Inc. (Amex: RNN), a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that it has signed an exclusive collaboration and option for license agreement with a top 20 global pharmaceutical company (the “Partner Co.”) for the development of RX-3117. RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that has an anti-metabolite mechanism of action, and has therapeutic potential in a broad range of cancers including colon, lung and pancreatic cancer.
The obligation of the Partner Co. to proceed with the transaction is subject to its satisfaction with its ongoing due diligence activities and to the satisfaction of other customary conditions. Assuming that the Partner Co. elects to proceed, then under the terms of the agreement, Rexahn will receive upfront payments in the form of equity investment and, assuming the license option is exercised, will be eligible to receive development, regulatory and sales milestone payments. In addition, Rexahn will receive royalties on net sales worldwide. The signing of the agreement by both parties precedes a definitive deal closing for the exclusive development and commercialization of RX-3117. Additional financial terms of the transaction were not disclosed.
Dr. Chang Ahn, Rexahn’s Chairman and Chief Executive Officer stated, “In addition to the strength of our Phase II compounds Archexin™, Serdaxin™ and Zoraxel™, the depth of our pre-clinical pipeline is a key differentiator of our company. The commitment of a big pharmaceutical partner to collaborate with Rexahn is a major step forward in our strategy and validates the commercialization value of our innovative pipeline. RX-3117 is a highly promising anticancer compound with potential for oral and IV formulation, and this new partnership serves to rapidly advance its development and helps us realize a potentially significant revenue stream.”
RX-3117 is a small molecule, new chemical entity (NCE), nucleoside compound that inhibits DNA methyltransferase, a cyclin-dependent kinase, and DNA synthesis. Potential indications of RX-3117 are solid tumors including colon, lung and pancreatic cancers. RX-3117 has demonstrated its ability to overcome cancer drug resistance in cancer cells, in particular, gemcitabine-resistance in the human lung cancer cell. The US patent issued for RX-3117 claims composition of matter, synthesis, and methods (2008).
ICO GLOBAL COMMUNICATIONS HOLDINGS LIMITED (NASDAQ: ICOG)
"Up 26.67% in morning trading"
ICO Global Communications Holdings Limited is a satellite communications company developing an advanced next-generation hybrid media system, combining both satellite and terrestrial communications capabilities. In North America, ICO is conducting trials for innovative new mobile services using a satellite-terrestrial network powered by ICO G1, which was launched in 2008. ICO’s satellites are capable of supporting wireless voice, data, and/or Internet services on mobile and portable devices. ICO is based in Reston, Virginia.
May 15 -
DBSD North America Inc. Files Pre-Negotiated Plan to Restructure Outstanding Debt
DBSD North America, Inc. (“DBSD” or the "Company"), formerly known as ICO North America, Inc. and a subsidiary of ICO Global Communications (Holdings) Limited (Nasdaq: ICOG) (ICO) (“ICO Global”), announced that it has filed a voluntary petition under Chapter 11 of the Bankruptcy Code in the United States Bankruptcy Court for the Southern District of New York in order to complete a restructuring of its $750 million of convertible notes which are due in August 2009 (the "Notes"). The Company and ICO Global have entered into agreements with holders of approximately 57% of the Notes to implement a plan of recapitalization pursuant to which holders of the Notes would receive shares of common stock of the reorganized company representing approximately 95% of the outstanding equity and ICO Global would receive shares of common stock representing approximately 5% of the outstanding equity. In addition, ICO Global would receive warrants to purchase at $0.01 per share up to an additional 10% of the equity which shall be exercisable upon certain valuation events.
DBSD anticipates that it will continue to operate in a business-as-usual manner during the restructuring process, subject to court approval. ICO Global is not involved in the Chapter 11 reorganization, and its operations and other assets including its judgment against The Boeing Company are not impacted by the DBSD restructuring process.
Michael Corkery, acting chief executive officer of ICO Global and DBSD said, “After a careful evaluation of all of our alternatives, DBSD and the majority of our note holders agreed that a Chapter 11 filing is the best way to implement the restructuring of the Notes. DBSD and its subsidiaries have made tremendous progress in the past year to lay the foundation for delivering innovative mobile satellite services. This restructuring will allow us to significantly improve the financial position for DBSD and its subsidiaries, and will also allow DBSD to focus on maximizing the value of its capabilities and assets.”
DBSD’s principal legal advisors for the restructuring process and Chapter 11 proceedings are Kirkland and Ellis, LLP, and Davis Wright Tremaine LLP. The Company’s financial advisor is Jefferies & Company, Inc. UBS Securities LLC acted as financial advisor, and Milbank, Tweed, Hadley & McCloy LLP acted as principal legal advisor to the note holders supporting the restructuring.
BIOVEST INTERNATIONAL INCORPORATED (OTCBB: BVTI)
"Up 26.32% in morning trading"
Biovest International, Inc. is a pioneer in the development of advanced individualized immunotherapies for life-threatening cancers of the blood system. Biovest is a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc., (NASDAQ: ABPI) with its remaining shares publicly traded. Biovest has a foundation in the manufacture of biologics for research and clinical trials. In addition, Biovest develops, manufactures and markets patented cell culture systems, including the innovative AutovaxID™, which is being marketed as an automated vaccine manufacturing instrument and for production of cell-based materials and therapeutics. Biovest is currently completing a pivotal Phase 3 clinical trial for BiovaxID®, which is a patient-specific anti-cancer vaccine focusing on the treatment of follicular non-Hodgkin's lymphoma. BiovaxID has been granted Fast Track status by the FDA and Orphan Drug status by the EMEA.
June 28 -
Personalized Anti-Cancer Vaccine, BiovaxID®, Targeting B-cell Lymphomas Available in Europe on a Named-Patient Basis
* Biovest and idis Partner to Facilitate Patient Access to Lymphoma Vaccine
* Phase III Study Results to Be Presented at “Best of ASCO” in Paris
Biovest International, Inc. (OTC: BVTI), a majority-owned subsidiary of Accentia Biopharmaceuticals, Inc. (OTC: ABPIQ) announced that BiovaxID®, Biovest’s personalized therapeutic anti-cancer vaccine, is available on a named-patient (compassionate-use) basis in Europe. Following compliance with local regulatory protocols, BiovaxID will be supplied by idis Limited to European healthcare professionals for the treatment of follicular non-Hodgkin’s lymphoma and potentially for other B-cell blood cancers such as chronic lymphocytic leukemia, mantle cell lymphoma and multiple myeloma. Physicians in non-European countries may also contact idis to inquire about the potential availability of BiovaxID, as idis manages named-patient programs in more than 100 countries.
According to world-renowned hematologist and lymphoma research pioneer, Professor Volker Diehl, M.D., Ph.D., Professor of Medicine, University of Cologne, “With the availability of this truly patient-specific vaccine, I believe hematologists now have a new, safe lymphoma treatment option capable of enhancing existing chemotherapeutic and monoclonal antibody treatment options by training the patient’s own immune system to selectively recognize and attack cancer cells, resulting in potentially longer lasting remissions. As follicular lymphoma so far is supposed to be a generally incurable and fatal blood cancer, it is with great hope and expectations that I welcome such a highly personalized therapeutic approach in addressing an urgent unmet need.” Prof. Dr. Diehl founded the German Hodgkin Study Group and is a recipient of the Bundesverdienstkreuz (Order of Merit of the Federal Republic of Germany), awarded by the German government for his lifetime achievements in the field of lymphoma research.
The BiovaxID Phase III study results were recently presented at the American Society of Clinical Oncology (ASCO) Annual Meeting Plenary Session, reporting that an eight year pivotal, randomized, multi-center, double-blind, controlled clinical study demonstrated that BiovaxID significantly prolonged disease-free survival in follicular non-Hodgkin’s lymphoma. The study found that patients who received BiovaxID experienced a median disease-free survival of 44.2 months compared to 30.6 months for those who received a control vaccine – an increase of 47 percent. In the study, with a median follow-up of 4.7 years, patients receiving BiovaxID experienced a 38% lower risk of disease recurrence compared to patients receiving the control vaccine. BiovaxID is the first vaccine targeting lymphoma ever to demonstrate such a disease-free survival benefit and because the vaccine is comprised of the patient’s own cells (autologous), the therapy has been demonstrated to be safe and well-tolerated.
Later today, the BiovaxID Phase III study results will again be presented at the “Best of ASCO” event to be held at the Maison de la Chimie, in Paris, France at 4:15 p.m. local time. The discussants for the BiovaxID abstract (abstract 33572) will be Jean-Luc Harousseau, M.D., Head of the Department of Clinical Hematology at the Central Laboratory of Hematology in Nantes, France and Vice President of the French Society of Hematology, and Christian Gisselbrecht, M.D., Ph.D., of the Institut d'Hématologie, Hôpital Saint-Louis in Paris, France.
Prof. Dr. Diehl also anticipates that the addition of BiovaxID booster shots could substantially bolster patient results, stating, “The recently reported Phase III results, while impressive, did not include a BiovaxID maintenance regimen consisting of periodic booster shots. Such a maintenance booster regimen may be key in continuing to stimulate a robust and enduring immune response, thus further improving results, and perhaps even resulting in durable remissions for some patients.” Biovest intends to include multiple booster vaccines for potential maintenance therapy purposes as part of the vaccine delivery for prescriptions processed under the named-patient program.
As BiovaxID is individually manufactured from a tissue biopsy obtained from a patient’s own tumor, a patient wishing to participate in the named-patient program must undergo a lymph node biopsy prior to receiving chemotherapy/monoclonal antibody therapy. Those cells collected by biopsy will then undergo a preparation process performed by Biovest with the resulting vaccine material then preserved until manufacture of the final vaccine is prescribed by the patient’s physician through idis. The vaccine is typically administered approximately 6 months following the end of chemotherapy, and consists of five BiovaxID vaccinations, subcutaneously injected, over a 6 month period (months 1,2,3,4 and 6). As an adjuvant therapy, at each vaccination cycle, patients will also receive four daily injections of an immune stimulating agent, GM-CSF. At the physician’s option, a periodic vaccine booster maintenance regimen may also be prescribed.
A named-patient program is a compassionate-use drug supply program under which physicians are permitted to supply investigational drugs to qualifying patients. Under a named-patient program, investigational drugs may be administered to patients who are suffering from a serious illness prior to the drug being approved by the European Medicines Evaluation Agency (EMEA). “Named-patient” distribution refers to the distribution or sale of a product to a specific healthcare professional for the treatment of an individual patient, assuming compliance with the local regulatory protocols respective to each participating country. In Europe, under the named-patient program, the drug is most often purchased through the national health system.
BiovaxID is a personalized, patient-specific therapeutic vaccine designed to stimulate the patient's own immune system to recognize and destroy cancerous B-cells that may remain in the body or may arise after the patient has been treated with chemotherapy. Unlike many other approaches to treating non-Hodgkin’s lymphoma, BiovaxID is designed to kill only cancerous B-cells, with the initial indication of follicular Non-Hodgkin's lymphoma. Additionally, it is anticipated that BiovaxID could be used to treat other types of B-cell cancers, such as mantle cell lymphoma, chronic lymphocytic leukemia and multiple myeloma.
A Unique Approach to Immunotherapy Targeting B-Cell Blood Cancers
B-cells (a type of white blood cell or lymphocyte) are a vital part of the human immune system, as they produce antibodies that seek out and bind to foreign substances in the body. In lymphoma, as cancerous B-cells develop and multiply unrestrained, each malignant B-cell expresses a unique idiotype or biomarker on the cell’s surface, specific to each patient. Research at Stanford University and the National Cancer Institute led to the development of BiovaxID as a personalized, therapeutic vaccine capable of selectively targeting only cancerous B-cells, while sparing healthy cells. This is achieved by using the idiotype obtained from a sample of the patient’s tumor by biopsy, and through proprietary bioengineering techniques in a patented cell line, a patient-specific vaccine is created that stimulates the immune system by recruiting a patient’s T-cells (immune cells that kill cancerous cells) to seek out and destroy only the diseased B-cells. BiovaxID is the only hybridoma (patient’s lymphoma cells are fused to a heteromyeloma cell line to produce the tumor specific idiotype protein) anti-cancer vaccine that consists of a high-fidelity copy of the complete idiotype, believed to be critical in mounting a full and complete immune response against the cancer, as well as “training” the immune system to maintain continuous response if cancerous cells were to return.
ABOUT IDIS LIMITED
idis is the world leader in the development and implementation of named-patient programs and has a proven track record of working in strategic partnership with US-based companies to bring new drugs to Europe for the first time. idis supports customers in over 100 countries, supplying more than 400 different medicines per month and responding to more than half a million requests on a named-patient basis to medical professionals worldwide.
SIRIUS XM RADIO INCORPORATED (NASDAQ: SIRI)
"Up 16.67% in morning trading"
SIRIUS XM Radio is America's satellite radio company delivering to subscribers commercial-free music channels, premier sports, news, talk, entertainment, and traffic and weather. SIRIUS XM Radio has content relationships with an array of personalities and artists, including Howard Stern, Martha Stewart, Oprah Winfrey, Jimmy Buffett, Jamie Foxx, Barbara Walters, Opie & Anthony, Bubba the Love Sponge®, The Grateful Dead, Willie Nelson, Bob Dylan, Tom Petty, and Bob Edwards. SIRIUS XM Radio is the leader in sports programming as the Official Satellite Radio Partner of the NFL, Major League Baseball®, NASCAR®, NBA, NHL®, and PGA TOUR®, and broadcasts major college sports. SIRIUS XM Radio has arrangements with every major automaker. SIRIUS XM Radio products are available at shop.sirius.com and shop.xmradio.com, and at retail locations nationwide, including Best Buy, RadioShack, Target, Sam's Club, and Wal-Mart. SIRIUS XM Radio also offers SIRIUS Backseat TV, the first ever live in-vehicle rear seat entertainment featuring Nickelodeon, Disney Channel and Cartoon Network; XM NavTraffic® service for GPS navigation systems delivers real-time traffic information, including accidents and road construction, for more than 80 North American markets.
June 29 -
SIRIUS XM's E Street Radio to Celebrate the Fourth of July With Concert Audio From Bruce Springsteen and the E Street Band's Current Tour
E Street Radio to broadcast select songs from Bruce Springsteen and the legendary E Street Band's concert in Frankfurt, Germany
SIRIUS XM Radio (Nasdaq: SIRI) announced that it will broadcast performances from a concert by Bruce Springsteen and the E Street Band scheduled to be recorded live on July 3, 2009 in Frankfurt, Germany from their current "Working On A Dream" tour. The rare broadcast will air on E Street Radio, the exclusive 100% commercial-free channel dedicated to the music of Bruce Springsteen and the E Street Band on Saturday, July 4 at 12:00 pm ET.
E Street Radio's extensive 4th of July programming will also include a performance by fellow Jersey-shore rocker Southside Johnny from the legendary Stone Pony in Asbury Park, New Jersey. The performance will be recorded live on Thursday, July 2 and will air on Friday, July 3 at 8:00 pm ET.
E Street Radio listeners will also hear archived Bruce Springsteen July 4th concerts from the past, including the July 4, 1985 concert at Wembley Stadium, England, the July 4, 1992 concert in Barcelona, Spain and specially selected songs from a performance in 2008 in Gothenburg, Sweden.
Lastly, to celebrate the 4th of July, E Street Radio will feature the best loved live "party songs" from the band's storied live performances, selected from various Springsteen concerts over the years.
E Street Radio, SIRIUS channel 10 and XM channel 58, gives SIRIUS XM listeners unprecedented access to the music of Bruce Springsteen and the E Street Band, including concert broadcasts, rare archival recordings as well as insider reports and breaking news.